Reference : Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Human health sciences : Immunology & infectious disease
Human health sciences : Rheumatology
http://hdl.handle.net/2268/98350
Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use
English
Hazes, Johanna M.W. [Erasmus Universiteit Rotterdam - EUR > Medicine > Rheumatology > >]
Coulie, Pierre G. [Université Catholique de Louvain - UCL > de Duve Institute > > >]
Geenen, Vincent mailto [Université de Liège - ULg > > Centre d'immunologie >]
Vermeire, Severine [Katholieke Universiteit Leuven - KUL > Gastroenterology > > >]
Carbonnel, Franck [Hôpital Bicêtre > Gastroentérologie > > >]
LOUIS, Edouard [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Masson, Pierre [Université Catholique de Louvain - UCL > de Duve Institute > > >]
De Keyser, Filip [Ghent University > Rheumatology > > >]
Sep-2011
Rheumatology
Oxford University Press
Yes (verified by ORBi)
International
1462-0324
1462-0332
Oxford
United Kingdom
[en] Pregnancy ; Rheumatoid arthritis ; Disease activity ; Pregnancy outcome ; Drug treatment ; Anti-TNF
[en] It has long been known that pregnancy and childbirth have a profound effect on the disease activity of rheumatic diseases. For clinicians, the management of patients with RA wishing to become pregnant involves the challenge of keeping disease activity under control and adequately adapting drug therapy during pregnancy and post-partum. This article aims to summarize the current evidence on the evolution of RA disease activity during and after pregnancy and the use of anti-rheumatic drugs around this period. Of recent interest is the potential use of anti-TNF compounds in the preconception period and during pregnancy. Accumulating experience with anti-TNF therapy in other immune-mediated inflammatory diseases, such as Crohn’s disease, provides useful insights for the use of TNF blockade in pregnant women with RA, or RA patients wishing to become pregnant.
Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS
Researchers ; Professionals
http://hdl.handle.net/2268/98350
10.1093/rheumatology/ker302
www.rheumatology.oxfordjournals.org

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Rheumatology-2011-Hazes-rheumatology_ker302.pdfAuthor postprint383.98 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.